



Imaging biomarkers are key to detecting and treating cancer

Press Release

MEDIAN Technologies Announces a new €205K Project Award

MEDIAN Technologies has been selected to manage medical images in a phase II clinical study for lung cancer sponsored by a global Top 10 pharmaceutical company

Sophia Antipolis, France – December 12, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today that it has been selected to provide imaging solutions and services in a new phase II clinical trial for Non-Small Cell Lung Cancer. The study is sponsored by a major global biopharmaceutical company.

Within the framework of the project, imaging data will be acquired from 20 clinical sites worldwide. Anticipated total enrollment is 50 patients with a forecasted start date early 2014. MEDIAN will provide on-site reading services based on the deployment of its MEDIAN LMS -Lesion Management Solutions- application software. MEDIAN LMS is a suite of software modules for the automated detection, quantification, and tracking of tumors in 3D medical images. It provides unique features for the review of images and quantitative assessment of response to therapy in clinical trials. Within the frame of the trial, response evaluation to therapy will be assessed using RECIST criteria and tumor volume growth, an advanced imaging biomarker. MEDIAN will also supply a set of services including clinical site training, as well as collection and quality control of image interpretations performed by the sites involved in the study.

The anticipated amount for the project is € 205,000 (eq. \$ 267,000).

“We have worked with this global top 10 pharmaceutical company since the creation of our imaging services offer to the pharmaceutical industry”, said Nicolas Dano, Director of Business Development, Europe and Asia. “Having this third consecutive study awarded with them demonstrates the relevance of our approach regarding the management of images in clinical trials as well as the quality of our services”.

Since the beginning of 2013, MEDIAN Technologies has recorded €4.7M of orders, including €1,0M of firm orders and €3.7M of project awards [*].

[] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.*



Imaging biomarkers are key to detecting and treating cancer

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world's largest CRO to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.medianttechnologies.com

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
+ 33 6 64 18 99 59
caroline@alizerp.com

Christian Berg
+ 33 1 70 22 53 86
christian@alizerp.com

Investors

ACTIFIN
Anaïs de Scitivaux
+ 33 1 56 88 11 14
adescitivaux@actifin.fr